EP2046331B1 — Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
Assigned to Celgene Corp · Expires 2010-11-03 · 16y expired
What this patent protects
The treatment, prevention or management of mantle cell lymphomas by administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide are disclosed. The invention further relates to the use of this compound with chemotherapy, radiation therapy, ho…
USPTO Abstract
The treatment, prevention or management of mantle cell lymphomas by administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide are disclosed. The invention further relates to the use of this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy for the claimed treatment. Pharmaceutical compositions and single unit dosage forms suitable for use in the invention are also disclosed.
Drugs covered by this patent
- Revlimid (lenalidomide) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.